
Alector Inc (ALEC) Stock Forecast & Price Target
Alector Inc (ALEC) Analyst Ratings
Bulls say
Alector Inc is developing promising therapies targeting neurodegeneration, highlighted by its novel approach utilizing the transferrin receptor (TfR) for enhanced brain delivery and systemic uptake. The robust early clinical pipeline, particularly with lead programs like AL137, AL050, and ADP064-ABC, represents significant potential due to their alignment with larger indications and the likelihood of generating positive proof-of-concept data. Furthermore, the differentiated platform shows substantial brain uptake and safety signals, bolstering the prospects for clinical success and potential shareholder value.
Bears say
Alector Inc's stock outlook has turned negative due to the failure of its INFRONT-3 trial for latozinemab, which did not meet its primary endpoint, thus highlighting significant translational biology risks alongside previous negative outcomes. Concerns surrounding the efficiency of PGRN transport and its implications for the company's therapeutic approach further exacerbate investment risks, particularly regarding the potential failures of key drug candidates AL001, AL002, and AL101 in clinical studies and regulatory approvals. The overall valuation assessment, based on a discounted cash flow analysis, incorporates a considerable risk of negative readouts from ongoing trials and possible unexpected side effects, raising the uncertainty of achieving projected commercial revenues.
This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.
Alector Inc (ALEC) Analyst Forecast & Price Prediction
Start investing in Alector Inc (ALEC)
Order type
Buy in
Order amount
Est. shares
0 shares